Prolonged bleeding can be life-threatening for individuals with inherited molecular defects in platelet proteins that play an intricate role in maintaining hemostasis. Transfusion with normal platelets or cryopreserved plasma components has been used for temporary relief of intermittent bleeding episodes, while bone marrow transplant has been used effectively for long-term correction of some patients with inherited bleeding disorders. Although, multiple transfusions are costly and can lead to the immune mediated destruction or inactivation of foreign platelets and coagulation factors. In addition, it can be difficult to find suitable marrow donors and recipients may also suffer deleterious effects from graft-vs-host disease and graft rejection. We have recently shown a potentially feasible solution for this problem by transferring a therapeutic gene with a lentivirus vector into hematopoietic stem cells. This strategy proved useful for correction of bleeding in the murine model for Glanzmann Thrombasthenia (GT). Individuals with GT have genetic defects in a member of the integrin family of adhesion receptors, allbbeta3. Molecular abnormalities in the sequences encoding either the allb or beta3 subunit prevent GT platelets from binding fibrinogen and forming platelet aggregates. Our gene transfer vector utilizes the allb gene promoter to confine transgene expression specifically to the platelet lineage. The current proposal will test the hypothesis that this platelet-specific lentivirus system can be utilized for therapeutic correction of bleeding in large animals affected with inherited platelet defects. A line of Great Pyrenees dogs affected with GT due to an abnormality in allb will serve as a model to test the feasibility for platelet-targeted gene therapy in large animals.
Specific Aim 1 will test novel strategies for their potential to increase transgene expression to 50% of normal levels on platelets derived from hematopoietic stem cells transduced with an allb gene promoter controlled lentivirus vector.
Specific Aim 2 proposes to develop a feasible approach for human gene therapy for inherited platelet bleeding disorders using a clinically relevant genetic transfer protocol in a canine model for GT.
In Specific Aim 3, an allb-driven lentivirus will be used to explore strategies to correct canine Hemophilia A via targeted synthesis and storage of coagulation factor VIII to platelet a-granules. This study should lead to the development of safe and effective methods for human gene therapy for inherited platelet bleeding disorders and other diseases of hemostasis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL068138-08
Application #
7881679
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Kindzelski, Andrei L
Project Start
2001-07-01
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2012-06-30
Support Year
8
Fiscal Year
2010
Total Cost
$338,038
Indirect Cost
Name
Medical College of Wisconsin
Department
Pediatrics
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Wilcox, David A (2016) Megakaryocyte- and megakaryocyte precursor-related gene therapies. Blood 127:1260-8
Schroeder, J A; Chen, Y; Fang, J et al. (2014) In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. J Thromb Haemost 12:1283-93
Du, Lily M; Nurden, Paquita; Nurden, Alan T et al. (2013) Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 4:2773
Zheng, Xiaodong; Zinkevich, Natalya S; Gebremedhin, Debebe et al. (2013) Arachidonic acid-induced dilation in human coronary arterioles: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca2+ entry. J Am Heart Assoc 2:e000080
Nurden, Alan T; Pillois, Xavier; Wilcox, David A (2013) Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost 39:642-55
Fang, J; Nurden, P; North, P et al. (2013) C560R?3 caused platelet integrin ?II b ?3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost 11:1163-71
Kuether, E L; Schroeder, J A; Fahs, S A et al. (2012) Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost 10:1570-80
Fang, Juan; Jensen, Eric S; Boudreaux, Mary K et al. (2011) Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A 108:9583-8
Mendoza, Suelhem A; Fang, Juan; Gutterman, David D et al. (2010) TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. Am J Physiol Heart Circ Physiol 298:H466-76
Shi, Qizhen; Fahs, Scot A; Wilcox, David A et al. (2008) Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood 112:2713-21

Showing the most recent 10 out of 19 publications